ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
APOE4 carriers display loss of anticipatory cerebrovascular regulation across the Alzheimer's disease continuum.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Comorbidity sequence, sex, and APOE-genotype forecast Alzheimer's disease diagnosis.Frontiers in medicine · 2026Article
- APOE4 carriers resistant to cognitive decline show unique relationships between cerebrovascular response to exercise and dual-task cognitive-balance performance.Frontiers in neuroscience · 2026Article
- APOE4 carriers resistant to cognitive decline show unique relationships between cerebrovascular response to exercise and dual-task cognitive-balance performance.bioRxiv : the preprint server for biology · 2025Article
- Synergistic effects of multiple pathological processes on Alzheimer's disease risk: Evidence for age-dependent stroke interactions.The journal of prevention of Alzheimer's disease · 2025Article
- APOE4 carriers display loss of anticipatory cerebrovascular regulation across the Alzheimer's disease continuum.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- The impact of high-intensity interval training on cerebrovascular function in the APP/PS1 mice.Frontiers in aging · 2025Article
- Cerebrovascular reactivity and plasma p-tau181 in Alzheimer's disease: Insights into APOE-related vascular phenotypes.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
backgroundMaintenance of cerebral blood flow during orthostasis is impaired with aging and associated with cognitive decline, but the effect of the apolipoprotein ɛ4 allele (APOE4) is unknown.
methodsOlder adults (n = 108) (APOE4 carriers, n = 47; non-carriers, n = 61) diagnosed as having normal cognition (NC), mild cognitive impairment (MCI), or Alzheimer's disease (AD) underwent transcranial Doppler ultrasound assessment of middle cerebral artery blood velocity (MCAv) and beat-to-beat mean arterial blood pressure (MAP) during a sit-to-stand transition. Anticipatory and orthostasis-induced MCAv and MAP responses were compared between genotypes and diagnostic classifications.
resultsCognitively normal APOE4 carriers showed greater anticipatory MCAv increase, greater MCAv decrease with orthostasis, and shorter latency of peripheral MAP responses to orthostasis compared to non-carriers. MCAv and MAP responses were delayed and attenuated across the APOE4 disease continuum, with no differences between genotypes in MCI and AD. DISCUSSION: Unique cerebral and peripheral vascular compensation observed in APOE4 carriers may be neuroprotective for AD development. HIGHLIGHTS: APOE4 carriers with NC show greater anticipatory increases in MCAv prior to orthostasis and decreases during orthostasis. APOE4 carriers with NC show faster peripheral MAP responses during orthostasis. APOE4 carriers with MCI and AD display loss of anticipatory MCAv responses. APOE4 carriers with MCI and AD display slower peripheral MAP responses. Unique cerebral and peripheral vascular compensation observed in APOE4 carriers may be neuroprotective for AD development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.